JUL 10, 2018 08:45 PM PDT

New Potential Inhibitor Target for Mantle Cell Lymphoma

WRITTEN BY: Mauri Brueggeman
2 1 88

Mantle Cell Lymphoma (MCL) is a rare form of non-Hodgkin’s Lymphoma (NHL) and is so named because of the cells involved.  The mantle is part of follicular zones which surround germinal centers within each lymph node.  The mantle cells become mutagenic and as the mantle cell population grows, the remainder of the lymph cells.  The disease primarily involves the lymph nodes and less often, in about 25% of cases, in the blood or bone marrow.  MCL is usually aggressive.  The morphology of MCL is very similar to Chronic Lymphocytic Leukemia; nuclear irregularities in the cell can be more prominent but are often indistinguishable from CLL cells.  There are molecular techniques that can be used to diagnose MCL including evaluating cell markers like B-cell antigens CD19, CD20 & CD22 and using fluorescence in-site hybridization (FISH) to characterize the present of a translocation between chromosome 11 and chromosome 14.  In 90% of cases of MCL, a protein called cyclin D1 is also present.  Clinicians use these tests and the evaluation of blood levels of lactate dehydrogenase (LDH) and beta-2 microglobulin to determine aggressiveness and guide therapeutic intervention.  The challenge is that while some patients diagnosed with MCL are young and can undergo chemotherapy and a bone marrow transplant, the larger majority have disease identified in their later years at age 68 or older.  There is a need for additional alternative treatments.  

One group of researchers published an article in Oncotarget last month outlining a novel therapeutic option for targeting MCL cells.  The gene product of BMI-1 is required for the growth of MCL cells and is found to be upregulated in MCL.  A selective inhibitor, called PTC596, has been reported to inhibit BMI-1 expression in these cells.  PTC596 initiated apoptosis in MCL cells. 

BMI-1 is a proto-oncogene and polycomb ring finger protein that plays a role in chromatin remodeling and epigenetic labeling processes for regulating embryonic development and self-renewal in stem cells.  It is also protein know to participate in DNA damage repair.  According to the literature published on BMI-1, its divergent expression can also mean resistance to chemotherapy.  The gene is found on chromosome 10 at 10p12.2 and the resultant protein has 326 amino acids. 

The Federal Drug Administration in the US approved acalabrutinib last October for the treatment of adults with MCL but those patients need to have been treated with at least one prior therapy.  This drug was approved using the FDA’s accelerated approval process because there has been such a need for treatment for this very aggressive form of cancer.  Another treatment approach is the use of ibrutinib, which binds to Bruton’s tyrosine kinase (BTK).  This drug has been helpful in the treatment of CLL and can reduce the tumor burden in combination with other therapies.

Sources: Oncotarget, Lymphoma Research Foundation, Therapeutic Advances in Hematology, GeneCardsSuite, FDA,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
APR 03, 2018
Drug Discovery
APR 03, 2018
Two-Drug Strategy for Non-Small Cell Lung Cancer (NSCLC)
According to the National Cancer Institute, lung cancer is the most common cause of cancer death for both men and women in the U.S. More specifically, non-
APR 06, 2018
Cancer
APR 06, 2018
PanCancer Atlas of 33 Cancer Types for Genomic Profile Index Completed by NIH TCGA
The Cancer Genome Atlas project used genomic profiles and bioinformatics to catalogue 33 prevalent types of cancer and is available to the public after 10+ years of analysis.
APR 18, 2018
Cancer
APR 18, 2018
Pedatric Pan Cancer Analysis Efforts Thus Far
Studies work toward a pediatric pan-cancer atlas similar to the larger scale adult cancer genome atlas. Approaches, diagnoses, prognoses, and treatments differ between adult and cancers of ch
MAY 16, 2018
Cancer
MAY 16, 2018
Ketogenic Diet Has Anti-Tumor Effects
The ketogenic diet has been found to have anti-tumor effects. Understanding the underlying mechanism of energy production in health and cancer cells provides the basis for the hypothesis.
JUN 26, 2018
Cancer
JUN 26, 2018
Genomic Markers Identified for Infant Soft Tissue Tumors
A new article from Nature Communications published on June 18, 2018 now outlines a newly discovered connection between infant soft tissue tumors and the mutations involving EGFR and BRAF gene
JUL 13, 2018
Genetics & Genomics
JUL 13, 2018
Detecting Leukemia Before it Starts Growing
Researchers have found ways to identify people who may develop an aggressive type of blood cancer while they are still healthy.
Loading Comments...